Drug intelligence / Profile preview

MCS-2

Development stage: Phase 3
Lead developer: Jyong Biotech
Modality: Small Molecules
Administration: Oral

Overview

MCS-2 is an investigational drug developed by Health Ever Bio-Tech Co., Ltd. and Jyong Biotech. It is administered as a soft-gel capsule and is being investigated for the treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH). Jyong Biotech, one of the developers, focuses on plant-based treatments, suggesting MCS-2 may be derived from natural sources.

Brand names: BOTRESO
Other names: BOTRESO

Beyond the preview

Go deeper on MCS-2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MCS-2.

Explore the full profile